Cyclic Peptide Ingredients TRIZ Cases

A 6-OH Trp amatoxin-linker boosts solid tumor cytotoxicity while cleavable antibody linkers balance targeted release and circulation stability.

An oral WS635 compound overcomes weak wound-care efficacy by inhibiting Cyclophilin D, promoting angiogenesis, and reducing wound area.

Position-4 OR4 substitution and a cleavable linker boost amatoxin antibody conjugate release and cytotoxicity against solid tumors.

Microwave-assisted transesterification converts cyclosporin A into isocyclosporin A salt with higher yield, shorter synthesis time, and lower toxicity.

Reduced-charge NAB815 blocks Shiga toxin 2 interaction with TLR4 at lower concentrations, helping treat HUS with less toxicity.

Surfactants mediate peptide transport across membranes, improving permeability and absorbability without changing target binding.

Position 3 substitution and PLGA embedding address the initial burst, retaining cyclosporine locally for stable release over one to four weeks.

This case pairs selected peptide compounds with carnitine-residue surfactants to improve Caco-2 permeability and absorbability.

This case combines salcaprozate sodium, nicotinamide, and protease inhibitors to protect peptides and improve oral bioavailability.

A low-toxicity reagent combination releases bound immunosuppressants from whole blood for accurate immunoassay without centrifugation.

Species-specific IL-31 mimotopes simplify anti-IL-31 antibody measurement and support vaccine development for atopic dermatitis.

A sustained release formulation incorporating a C5 inhibitory cyclic polypeptide combined with a poly lactic-co-glycolic acid matrix.

Self-microemulsifying drug delivery system enhances CRV431 solubility via pseudo-ternary phase formulation.

Compounds blocking Biliverdin reductase B binding sites increase platelet counts while avoiding cytotoxicity and multimerization of xanthene-based inhibitors.

Oleate-based self-emulsifying formulations bypass first-pass metabolism to increase bioavailability and absorption of hydrophobic compounds.

Establishing immune tolerance for liver allografts via bone marrow infusion to eliminate immunosuppressant complications.

Cleavable linkers stabilize amanitin in blood plasma until endocytosis releases the toxin at target sites.

Modular cyclic structures enhance peptide stability and reduce inflammatory side effects while lowering production costs.

Melanocortin receptor agonists combine with protease inhibitors and absorption enhancers to enable effective oral delivery of peptide drugs.

Cyclosporin derivatives bind host cyclophilins to block viral replication, reducing drug resistance in hepatitis treatment.

A DNA oligonucleotide selectively binds to IFN-gamma to inhibit activity.

Replacing NMP with specific PEG grades resolves storage stability and toxicity trade-offs in injectable depot systems.

Synthetic peptides induce wound closure through ERK1/2 signaling, resolving instability and manufacturing difficulties of growth factors.

Cyclic backbone peptides bind MD2 and CD14 co-receptors to resolve the trade-off between specific binding affinity and independent TLR4 signaling modulation.

An acidic buffer stabilizes daptomycin in liquid form, preventing degradation during long-term storage.

Low dose cyclosporine A inhibits prolactin-responsive cancer cell growth via cyclophilin binding.

Amanitin conjugates link cytotoxic payloads to PSMA-targeting small molecules via engineered linkers for cancer therapy.

Removes preservatives to prevent eye damage while maintaining sterility through disposable packaging and high-pressure homogenization.

Peptide mimetics inhibit EGFR kinase activity by targeting the juxtamembrane segment, overcoming resistance from ATP-site inhibitors.

Repurposed pharmaceutical compositions inhibit fungal growth, addressing limited treatment options and high development costs for Valley Fever.

Liposomal carriers increase epithelial lining fluid concentrations while reducing renal nephrotoxicity.

Structural variants of AIP-III peptides inhibit AgrC receptors, reducing TSST-1 production by over 80% without triggering antibiotic resistance development.

Boronic acid protection stabilizes fragile hemiaminal moieties, preventing racemization and boosting yield during semi-synthetic cyclopeptide preparation.

A hydrogel ionic circuit device applies electrical current to transport therapeutic ions across wound surfaces.

Ethosome vesicles encapsulate medications to penetrate the stratum corneum, reducing systemic toxicity from oral immunosuppressants.

NGAL conjugates deliver cyclosporin to renal tissue, reducing systemic toxicity while maintaining therapeutic efficacy.

Blue light photobleaches staphyloxanthin in MRSA membranes, creating pores that enable hydrogen peroxide synergy to eradicate antibiotic-resistant bacteria.

ZIZIT peptides block calcineurin-NFAT interaction to reduce systemic toxicity from broad-spectrum inhibitors.

Synthesized compounds overcome antibiotic resistance in Acinetobacter baumannii via parameter changes and composite materials.